Daiichi Sankyo Company has entered into a strategic collaboration with AgonOx, a Portland, Oregan-based biotechnology company developing a pipeline of immunotherapy cancer drugs, to develop an undisclosed immuno-oncology target. Under the agreement, Daiichi Sankyo and AgonOx will collaborate on preclinical development of the program. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research, develop, manufacture, and commercialize the program worldwide. Financial terms of the agreement were not disclosed.

Source: Daiichi Sankyo